Aylin Arslan

Dr. Aylin Arslan


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
HKHaluk Kerim Karakullukcu
Haluk Kerim Karakullukcu
HAHatice Aygun
Hatice Aygun
MKMurat Kalın
Murat Kalın
MKMina Karakullukcu
Mina Karakullukcu
AAAylin Arslan
Aylin Arslan
GEGulcin Ercan
Gulcin Ercan
Objectives: Doxorubicin (DOX) is an effective chemotherapeutic agent, but its clinical use is limited by hepatotoxicity associated with oxidative stress and inflammatory signaling. This study aimed to investigate the potential protective effects of melatonin and agomelatine on DOX-induced hepatic injury using scintigraphic, biochemical, and molecular parameters. Methods: Twenty-eight rats were randomly divided into four groups: Control, DOX, DOX + Melatonin, and DOX + Agomelatine. Melatonin and agomelatine were administered as a one-week pretreatment, and DOX was injected during the experimental period (total dose: 18 mg/kg). Hepatic injury was evaluated using 99mTc-PYP scintigraphic imaging, serum liver enzymes (AST, ALT, and LDH), oxidative stress markers (MDA, GSH, Nrf2, and SIRT1), and inflammatory cytokines (TNF-α, IL-6, and IL-10). Results: DOX administration significantly increased hepatic 99mTc-PYP uptake, as well as serum AST, ALT, and LDH levels, indicating hepatocellular necrosis and membrane damage. DOX also increased MDA, TNF-α, and IL-6 levels while reducing GSH, Nrf2, SIRT1, and IL-10, demonstrating pronounced oxidative stress and inflammatory activation. Treatment with melatonin or agomelatine significantly reduced tracer uptake and liver enzyme levels compared with the DOX group. Both treatments improved antioxidant status by decreasing MDA and restoring GSH, Nrf2, and SIRT1 levels, while simultaneously attenuating inflammatory cytokine responses through reduction in TNF-α and IL-6 and partial restoration of IL-10. Conclusions: Melatonin and agomelatine attenuated DOX-induced hepatotoxicity by reducing oxidative stress, modulating inflammatory responses, and restoring hepatic SIRT1 and Nrf2 levels. These findings suggest that melatonergic interventions may represent promising protective strategies against doxorubicin-induced liver injury.

15 July 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HKHaluk Kerim Karakullukcu
Haluk Kerim Karakullukcu
SGSerdar Savaş Gül
Serdar Savaş Gül
HAHatice Aygun
Hatice Aygun
MKMurat Kalın
Murat Kalın
MKMina Karakullukcu
Mina Karakullukcu
GEGulcin Ercan
Gulcin Ercan
Background: Doxorubicin is an effective antineoplastic agent, but its use is constrained by off-target toxicities, including acute liver injury driven by mitochondrial dysfunction, oxidative stress, sterile inflammation, and redox-sensitive signaling pathways. Exenatide, a glucagon-like peptide-1 receptor agonist, exerts antioxidant and anti-inflammatory effects in several experimental liver injury models, but its role in doxorubicin-induced hepatic injury has not been investigated to our knowledge. This study evaluated whether exenatide attenuates acute doxorubicin-induced hepatic injury and examined whether the observed biochemical changes are consistent with modulation of oxidative stress and SIRT1–HMGB1/NF-κB-related signaling. Methods: Male Wistar albino rats were allocated to four groups (n = 7/group): control, exenatide, doxorubicin, and exenatide + doxorubicin. Exenatide (10 µg/kg/day, intraperitoneally) was administered for seven days. Doxorubicin was given intraperitoneally on days 5–7 at a cumulative dose of 18 mg/kg. The pretreatment design was used to test preventive attenuation rather than reversal of established injury. Hepatic injury-associated enzyme activities, serum HMGB1, hepatic SIRT1, NF-κB, TNF-α, IL-6, IL-10, malondialdehyde, glutathione, total antioxidant status, total oxidant status, nitric oxide, and hepatic 99mTc-pyrophosphate uptake were assessed. Results: Doxorubicin substantially increased intrahepatic ALT and AST activities, serum HMGB1, hepatic NF-κB, TNF-α, IL-6, malondialdehyde, total oxidant status, nitric oxide, and hepatic 99mTc-pyrophosphate uptake, while reducing SIRT1, IL-10, glutathione, and total antioxidant status. Relative to the doxorubicin group, exenatide lowered HMGB1 by 48.3%, hepatic 99mTc-pyrophosphate uptake by 48.7%, malondialdehyde by 45.0%, total oxidant status by 37.3%, nitric oxide by 40.7%, NF-κB by 40.4%, TNF-α by 48.6%, and IL-6 by 41.1%, while increasing SIRT1 by 91.7%, IL-10 by 115%, glutathione by 115%, and total antioxidant status by 87.8%. None of the altered parameters returned completely to control levels, indicating attenuation rather than full normalization of acute injury-related changes. Conclusions: Exenatide attenuated doxorubicin-induced acute hepatic injury in this rat model and was associated with reduced oxidative stress, reduced inflammatory activation, higher hepatic SIRT1 levels, lower serum HMGB1 levels, and reduced hepatic 99mTc-pyrophosphate uptake. The findings are consistent with involvement of SIRT1–HMGB1/NF-κB-related signaling, but they do not establish causality. Hepatic 99mTc-pyrophosphate uptake should be interpreted as an exploratory imaging correlate of tissue injury rather than an established liver biomarker. Additional studies incorporating histopathology, immunohistochemistry, functional liver indices, mechanistic validation of SIRT1, and tumor-bearing models are required before translational conclusions can be drawn.

6 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
MKMurat Kalın
Murat Kalın
HAHatice Aygun
Hatice Aygun
HKHaluk Kerim Karakullukcu
Haluk Kerim Karakullukcu
MKMina Karakullukcu
Mina Karakullukcu
AAAylin Arslan
Aylin Arslan
GEGulcin Ercan
Gulcin Ercan
Background and Objectives: Doxorubicin is an antineoplastic drug used to treat cancer. However, side effects limit its use. Edaravone (EDO) is a recently discovered, powerful drug with antioxidant properties. The aim of the present study was to show the negative effects of doxorubicin and the protective effect of EDO on the thyroid gland using scintigraphic and biochemical methods. Materials and Methods: Thirty-five male Wistar rats were randomly divided into five groups (n = 7) to establish the following study groups: control, doxorubicin, and 1, 10, or 30 mg/kg EDO. DOX (18 mg/kg cumulative intraperitoneal injection (i.p.) was performed on the 19th, 20th, and 21st days of the experiment. EDO (1, 10, and 30 mg/kg) was administered on the first day of the trial and continued for 21 days. These groups also received i.p. injections of DOX (18 mg/kg) on the 19th, 20th, and 21st days of the experiment. On the 22nd day of the experiment, scintigraphic imaging of the thyroid glands of rats was performed using 99mTc pertechnetate as the radiopharmaceutical. Serum levels of T3, T4, TSH, NLRP3, IL-1β, and IL-18, as well as thyroid tissue levels of MDA, TNF-α, and IL-6, were determined using the ELISA method. Results: DOX significantly reduced 99mTc pertechnetate uptake in the thyroid gland compared to the control group (p < 0.001). It reduced plasma levels of thyroid hormones T3 (p < 0.001) and T4 (p < 0.001) while increasing TSH levels (p < 0.01). Additionally, NLRP3, IL-1β, IL-18, MDA, TNF-α, and IL-6 levels were significantly increased in the DOX group compared with the control group (all p < 0.001). Pretreatment with EDO significantly attenuated doxorubicin-induced abnormalities in the thyroid gland (p < 0.001). Conclusions: The data from scintigraphic and biochemical analyses revealed the development of hypothyroidism after doxorubicin administration in rats. It was shown that pretreatment with EDO could partially prevent hypothyroidism caused by doxorubicin.

14 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
KKKubilay Kemertaş
Kubilay Kemertaş
CDCengiz Dibekoglu
Cengiz Dibekoglu
Mert ZeytinoğluMert Zeytinoğlu
Mert Zeytinoğlu
HAHatice Aygun
Hatice Aygun
AAAylin Arslan
Aylin Arslan
OEOytun Erbas
Oytun Erbas
Background/Objectives:This study aimed to evaluate whether early renal perfusion scintigraphy is associated with sepsis severity and short-term mortality in an experimental polymicrobial sepsis model. Methods: A total of 90 female Wistar albino rats were divided into Control, mild sepsis, and severe sepsis groups using a cecal ligation and puncture (CLP) model. Renal perfusion was evaluated 5 h after sepsis induction using technetium-99m-labeled erythrocyte scintigraphy, expressed as the kidney-to-aorta (R/A) activity ratio. Survival was monitored for 5 days. Histopathological and biochemical analyses were also performed. Results: The kidney-to-aorta (R/A) activity ratio decreased progressively with increasing sepsis severity (all p < 0.001). Kaplan–Meier analysis demonstrated significantly reduced survival in septic animals (log-rank p < 0.001). The R/A ratio showed high discrimination for 5-day mortality (AUC = 0.944, 95% CI 0.902–0.986; p < 0.001). Univariable Cox proportional hazards analysis demonstrated that a lower R/A ratio was significantly associated with an increased hazard of death (HR = 0.005, 95% CI 0.001–0.036; p < 0.001). Histopathological injury scores and biochemical markers (TNF-α, VEGF, STAT3, NGAL, BUN, creatinine, and MDA) increased significantly with sepsis severity. Conclusions: Early Tc-99m-labeled erythrocyte renal perfusion scintigraphy was associated with sepsis severity and short-term mortality in experimental polymicrobial sepsis. These findings support further investigation of this imaging approach as an experimental marker of sepsis severity and outcome; however, external validation is required before clinical translation.

29 March 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
MKMurat Kalın
Murat Kalın
HKHaluk Kerim Karakullukcu
Haluk Kerim Karakullukcu
MKMina Karakullukcu
Mina Karakullukcu
AAAylin Arslan
Aylin Arslan
SGSerdar Savaş Gül
Serdar Savaş Gül
HAHatice Aygun
Hatice Aygun
Objectives: Doxorubicin, a widely used chemotherapeutic agent, is known to induce hepatotoxicity through oxidative stress and inflammatory pathways. Vitamin D has been reported to exert antioxidant and immunomodulatory effects; however, its potential protective role in doxorubicin-induced liver injury remains insufficiently characterized. Materials and Methods: Adult male Wistar albino rats were randomly assigned to six groups (n = 7): Control, Vitamin D (5000 IU/kg), Vitamin D (60,000 IU/kg), Doxorubicin, DOX + Vitamin D (5000 IU/kg), and DOX + Vitamin D (60,000 IU/kg). Vitamin D3 (cholecalciferol) was administered orally either as a daily dose (5000 IU/kg for 12 days) or as a single bolus dose (60,000 IU/kg). Doxorubicin (6 mg/kg/day, cumulative dose 18 mg/kg) was administered intraperitoneally on days 10–12. Hepatic injury was evaluated using 99mTc-pyrophosphate (99mTc-PYP) scintigraphy, serum liver enzymes (AST, ALT, LDH, total bilirubin), renal markers (BUN, creatinine), calcium and 25-hydroxyvitamin D [25(OH)D], oxidative stress parameters (MDA, TOS, TAS, GSH, SOD, Nrf2), and inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-10). Results: Doxorubicin markedly increased hepatic 99mTc-PYP uptake and significantly elevated AST, ALT, LDH, bilirubin, MDA, TOS, TNF-α, IL-6, and IL-1β levels while reducing Nrf2, GSH, SOD, TAS, and IL-10 (all p < 0.001). Vitamin D supplementation significantly increased serum 25-hydroxyvitamin D [25(OH)D] levels compared with controls (32.3 ± 2.7 vs. 74.1 ± 3.8 and 69.3 ± 3.2 ng/mL for the 5000 and 60,000 IU/kg groups, respectively; p < 0.001) and attenuated DOX-induced hepatic injury, as indicated by reduced radiotracer uptake and improved oxidative and inflammatory markers. Vitamin D also mitigated DOX-associated increases in renal injury markers (BUN and creatinine) without inducing hypercalcemia. No significant differences were observed between the two vitamin D dosing regimens in most outcome measures. Conclusion: Vitamin D supplementation exerted protective effects against doxorubicin-induced liver injury, likely through modulation of oxidative stress and inflammatory pathways. Additionally, 99mTc-PYP scintigraphy may serve as a useful imaging tool for detecting acute hepatocellular injury and evaluating therapeutic responses.